Overview
Diffuse Large B-Cell Lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL) worldwide, accounting for approximately 30% to 40% of all NHL cases in adults. It is an aggressive (fast-growing) malignancy arising from B-lymphocytes, a type of white blood cell responsible for producing antibodies to fight infection.
Despite its aggressive nature, DLBCL is potentially curable with modern immunochemotherapy regimens. The standard first-line treatment, R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone), results in long-term remission for approximately 60–70% of patients. Advances in molecular subtyping, targeted therapies, and chimeric antigen receptor (CAR) T-cell therapy have significantly improved outcomes for patients with relapsed or refractory disease.
This article provides a detailed, structured overview of DLBCL, covering epidemiology, pathophysiology, clinical presentation, diagnostic workup, staging, treatment paradigms, prognosis, and survivorship.
Epidemiology and Risk Factors
Incidence and Demographics
- Annual Incidence: Roughly 5–7 cases per 100,000 people per year in Western countries.
- Age: Median age at diagnosis is 65–70 years. Incidence rises sharply with age; it is rare in children and young adults but increases exponentially after age 50.
- Sex: Slight male predominance (Male-to-Female ratio ~1.5:1).
- Geography/Ethnicity: Highest rates in North America, Europe, and Australia; lower rates in Asia. In the US, incidence is higher in White populations compared to Black or Asian populations.
Established Risk Factors
While the exact cause remains unknown for most patients, several factors increase susceptibility:
| Risk Factor Category | Specific Factors | Mechanism/Association |
|---|---|---|
| Immunodeficiency | HIV/AIDS, Post-transplant immunosuppression (PTLD), Primary immunodeficiencies (e.g., CVID, Ataxia-telangiectasia) | Loss of immune surveillance allows uncontrolled B-cell proliferation driven by EBV or genomic instability. |
| Autoimmune/Chronic Inflammation | Rheumatoid arthritis, SLE, Sjögren’s syndrome, Celiac disease, IBD | Chronic antigenic stimulation of B-cells; immunosuppressive treatments (e.g., methotrexate, TNF-alpha inhibitors) may contribute. |
| Infectious Agents | Epstein-Barr Virus (EBV): Strong link in immunocompromised & elderly (EBV+ DLBCL).<br>Helicobacter pylori: Linked to gastric MALT lymphoma transformation.<br>Hepatitis C Virus (HCV): Chronic stimulation. | Viral oncoproteins (LMP1, EBNA2) drive proliferation; chronic inflammation causes genomic damage. |
| Iatrogenic | Prior chemotherapy/radiotherapy for other cancers | Therapy-related myeloid neoplasms/lymphomas (t-DLBCL), often with complex karyotypes (TP53 mutations). |
| Genetic/Familial | Family history of NHL (1.5–3x increased risk) | Shared genetic susceptibility loci (e.g., HLA region variants identified in GWAS). |
| Lifestyle/Environment | Obesity (BMI >30), Occupational exposure (pesticides, solvents, hair dyes – weak/conflicting evidence) | Chronic inflammatory state; potential DNA adduct formation. |
The majority of patients diagnosed with DLBCL have no identifiable risk factors. It is largely a disease of sporadic genomic accidents during B-cell differentiation.
Pathophysiology and Molecular Subtypes
DLBCL originates from mature B-cells arrested at the centroblast/immunoblast stage of differentiation, typically within the germinal center of lymphoid follicles. Normal germinal center B-cells undergo rapid proliferation, somatic hypermutation (SHM), and class-switch recombination (CSR)—processes mediated by the enzyme AID (Activation-Induced Cytidine Deaminase). Errors in these high-risk processes lead to translocations and mutations.
Cell of Origin (COO) Classification (Hans Algorithm / Gene Expression Profiling)
This is the most fundamental biological division, with distinct prognostic and therapeutic implications.
| Subtype | Cell of Origin | Key Genetic Features | Clinical Behavior | Standard IHC Markers (Hans) |
|---|---|---|---|---|
| GCB (Germinal Center B-Cell) | Germinal center centroblast | BCL2 translocation t(14;18), EZH2 mutations, BCL6 translocations, MEF2B mutations. | Better prognosis with R-CHOP; ~50-55% of cases. | CD10+ OR BCL6+ / MUM1- |
| ABC (Activated B-Cell) | Post-germinal center (plasmablastic) | MYD88 L265P, CD79B mutations, CARD11 mutations, BCL6 mutations (negative regulation lost), NF-κB pathway activation. | Worse prognosis with R-CHOP; higher CNS relapse rate; ~35-40% of cases. | CD10- / BCL6- / MUM1+ OR BCL6+ / MUM1+ |
| Unclassified (Type 3) | Indeterminate | Heterogeneous; features of both or neither. | Intermediate prognosis. | Does not fit Hans algorithm. |
“Double-Hit” and “Double-Expressor” Lymphomas (High-Grade Aggressive Variants)
These define a biologically distinct, highly aggressive spectrum requiring intensified or novel approaches.
- Double-Hit Lymphoma (DHL): Concurrent translocations of MYC (8q24) and BCL2 (18q21) and/or BCL6 (3q27). Confirmed by FISH.
- Triple-Hit: MYC + BCL2 + BCL6.
- Prognosis: Very poor with standard R-CHOP (2-yr PFS ~30-40%).
- Double-Expressor Lymphoma (DEL): MYC protein overexpression (≥40%) AND BCL2 protein overexpression (≥50%) by IHC, without the concurrent translocations.
- Prognosis: Inferior to standard DLBCL, but better than true DHL.
- High-Grade B-Cell Lymphoma (HGBCL), NOS: Morphologically blastic/pleomorphic, high Ki-67 (>90%), but lacking double-hit genetics.
Other Distinct Molecular Subtypes (WHO 2022 / ICC 2022)
Modern classifications integrate genetics (LymphGen, COO, Genetic Subtypes):
- MCD (MYD88/CD79B): Enriched in ABC; responds to BTK inhibitors (Ibrutinib).
- BN2 (BCL6/NOTCH2): Enriched in ABC; distinct immune microenvironment.
- N1 (NOTCH1): Distinct genomic profile.
- EZB (EZH2/BCL2): Enriched in GCB; EZH2 mutations sensitive to EZH2 inhibitors (Tazemetostat).
- ST2 (SGK1/TET2): Enriched in GCB.
- TP53 mutated / Complex Karyotype: Associated with chemoresistance and very poor outcomes.
How Does It Look? (Pathology, Imaging, and Gross Appearance)
This section details the visual and microscopic characteristics clinicians and pathologists use to identify DLBCL.
1. Gross Pathology (Macroscopic Appearance)
- Lymph Nodes: Typically enlarged, rubbery/firm, and non-tender. On cut surface, they appear homogeneously pale tan to white (fish-flesh appearance), bulging out of the capsule. Necrosis or hemorrhage is uncommon in untreated nodes but may be seen in bulky, rapidly growing tumors.
- Extranodal Sites (Common):
- Gastrointestinal Tract: Polypoid masses, circumferential wall thickening (“apple core” lesion), or ulcerated lesions (stomach > small bowel > colon).
- Testes: Firm, homogeneous enlargement replacing testicular parenchyma; often bilateral involvement at diagnosis or relapse.
- CNS (Primary CNS Lymphoma): Solitary or multiple ring-enhancing lesions on MRI, often periventricular, crossing corpus callosum (“butterfly glioma” mimic).
- Skin: Red-to-violaceous nodules, plaques, or tumors (Leg-type vs. non-leg type).
- Bone: Lytic lesions on X-ray/CT; “moth-eaten” appearance.
2. Microscopic Pathology (Histology – H&E Stain)
- Architecture: Diffuse effacement of normal lymph node architecture. No residual follicles or sinuses.
- Cell Morphology:
- Centroblastic (Most Common): Large cells (2–4x small lymphocyte size), round/oval nuclei, fine chromatin, 2–4 distinct nucleoli (often peripheral), scant basophilic cytoplasm. High mitotic count.
- Immunoblastic: Large cells with abundant pale cytoplasm, central single prominent nucleolus (plasmablastic differentiation). Associated with immunodeficiency/EBV.
- Anaplastic/Pleomorphic: Marked nuclear pleomorphism, bizarre multinucleated forms (Reed-Sternberg-like), high Ki-67. Overlaps with HGBCL.
- Microenvironment: Variable tumor-associated macrophages (TAMs), T-cells, and follicular dendritic cell meshworks (CD21/23 highlight residual networks).
- Necrosis/Apoptosis: “Starry-sky” pattern (tingible body macrophages ingesting apoptotic debris) is common but not specific (also seen in Burkitt Lymphoma).
3. Immunohistochemistry (IHC) Profile – The Diagnostic Fingerprint
Diagnosis requires a panel to confirm B-cell lineage, exclude mimics, and assign COO.
| Marker | Typical Result in DLBCL | Significance |
|---|---|---|
| CD20 | Positive (Nearly 100%) | Target for Rituximab; defines B-cell lineage. |
| PAX5 | Positive (Strong) | B-cell transcription factor; confirms lineage even if CD20 weak/lost. |
| BCL6 | Positive (80-90%) | Germinal center marker; transcription factor. |
| CD10 | Variable (30-50%) | Germinal center marker; defines GCB subtype if +. |
| MUM1/IRF4 | Variable (40-60%) | Late germinal center/post-GC marker; defines ABC if + (with CD10-). |
| BCL2 | Positive (50-70%) | Anti-apoptotic; t(14;18) hallmark. Prognostic in GCB. |
| MYC | Variable (20-30% high expression) | Proliferation driver; >40% defines “Double Expressor” (with BCL2+). |
| Ki-67 | High (usually >40%, often 70-90%) | Proliferation index; >90% suggests HGBCL/Burkitt. |
| CD30 | Positive (~15-20%) | Activation marker; predicts response to Brentuximab Vedotin (in trials). |
| EBER (ISH) | Negative (usually) | Positive = EBV+ DLBCL (distinct entity, often elderly/immunocompromised). |
| Cyclin D1 | Negative | Excludes Mantle Cell Lymphoma (blastoid variant). |
| SOX11 | Negative | Excludes Mantle Cell Lymphoma. |
| ALK | Negative | Excludes ALK+ Large B-Cell Lymphoma / ALCL. |
| HHV-8 (LANA1) | Negative | Excludes Primary Effusion Lymphoma / HHV8+ DLBCL. |
4. Radiological Appearance (Imaging)
- CT (Computed Tomography) – Standard for Staging/Response:
- Nodes: Homogeneous soft-tissue attenuation (40–60 HU). Necrosis (low attenuation center) suggests rapid growth or post-treatment change. “Lymphomatous polyposis” in bowel.
- Extranodal: Organomegaly (splenomegaly >13cm), discrete masses (liver, kidney, adrenal), bowel wall thickening (>1cm) with preservation of mucosa (vs carcinoma).
- PET-CT (FDG-Avid) – Gold Standard for Staging & Response Assessment:
- Intense FDG Uptake: SUVmax typically 10–30+ (highly metabolic).
- Deauville Score (5-Point Scale): Used for End-of-Treatment (EOT) and Interim (iPET) assessment.
- Score 1–3: Negative/Complete Metabolic Response (CMR).
- Score 4–5: Positive/Residual Disease (requires biopsy confirmation).
- MRI: Superior for CNS, spinal cord, bone marrow, and testicular involvement.
- Ultrasound: Initial test for testicular/scrotal masses; guides biopsy.
Symptoms: Clinical Presentation
DLBCL presents with rapidly progressive symptoms, typically evolving over weeks to a few months. The clinical picture depends heavily on the anatomic site of involvement.
1. Nodal Presentation (Most Common: ~60-70%)
- Painless Lymphadenopathy: Rapidly enlarging nodes, most frequently cervical, axillary, inguinal, or femoral.
- Bulk: Often “bulky” at diagnosis (>10 cm mass or >1/3 thoracic diameter).
- Compression Syndromes: Large mediastinal/retroperitoneal masses can cause:
- Superior Vena Cava (SVC) Syndrome: Facial/arm swelling, dyspnea, distended neck veins (Medical Emergency).
- Airway Compression: Stridor, cough, orthopnea.
- Ureteral Obstruction: Hydronephrosis, renal failure.
- Vascular Compression: DVT (ileofemoral), arterial compromise.
2. Extranodal Presentation (~30-40% at Diagnosis)
DLBCL is the most common NHL to present primarily at extranodal sites.
| Site | Frequency | Typical Symptoms / Signs |
|---|---|---|
| Gastrointestinal (Stomach #1) | 15–20% | Epigastric pain, early satiety, nausea, vomiting, GI bleeding (melena/hematemesis), weight loss, gastric outlet obstruction. |
| Bone | 10–15% | Localized bone pain (often night pain), pathologic fracture, spinal cord compression (emergency). |
| Skin / Soft Tissue | 10–15% | Rapidly growing nodules, ulcers, plaques (Leg type: lower legs, elderly women). |
| Central Nervous System (PCNSL) | 4–5% | Focal neurologic deficits (hemiparesis, aphasia), seizures, personality change, cranial nerve palsies, headache (ICP). |
| Testes | 2–5% (Males) | Painless testicular swelling/mass; often bilateral at relapse. B-symptoms rare. |
| Thyroid | Rare | Rapidly enlarging neck mass, compressive symptoms (dysphagia, stridor), often euthyroid. |
| Breast | Rare | Painless mass, skin thickening/retraction (mimics inflammatory carcinoma). |
| Adrenal | Rare | Adrenal insufficiency (fatigue, hypotension, hyponatremia) or incidental mass. |
3. Constitutional “B Symptoms” (Prognostic Factors)
Defined by Ann Arbor / Cotswolds criteria. Presence upstages disease (e.g., Stage IIB).
- Fever: Temperature >38°C (100.4°F) unexplained by infection, often Pel-Ebstein pattern (cyclical fevers over days/weeks) – less common now.
- Drenching Night Sweats: Requiring change of bedclothes/sheets.
- Unintentional Weight Loss: >10% of baseline body weight over 6 months preceding diagnosis.
4. Paraneoplastic & Rare Syndromes
- Autoimmune Hemolytic Anemia (AIHA) / Immune Thrombocytopenia (ITP): Coombs-positive hemolysis; may precede lymphoma diagnosis.
- Hypercalcemia: Rare in DLBCL (more common in T-cell); due to PTHrP or 1,25-Vit D production.
- Nephrotic Syndrome: Membranous nephropathy or minimal change disease.
- Neurologic Paraneoplastic: Limbic encephalitis, cerebellar degeneration (anti-Ma2, anti-Hu antibodies – rare).
5. Laboratory Abnormalities at Presentation
- LDH (Lactate Dehydrogenase): Elevated in ~50-70%. Surrogate for tumor burden and proliferation. Key component of IPI.
- CBC: Usually normal early on. Anemia (chronic disease, marrow infiltration, AIHA), Thrombocytopenia (marrow involvement, ITP, hypersplenism), Leukocytosis/Leukopenia.
- ESR/CRP: Often elevated (inflammatory cytokine release).
- Serum Protein Electrophoresis: Polyclonal hypergammaglobulinemia or, rarely, monoclonal gammopathy (IgM/IgG).
- Uric Acid: Elevated (tumor lysis risk).
- Hepatitis B/C, HIV Serology: Mandatory before immunosuppression (reactivation risk).
Diagnostic Workup: The “Must-Do” Checklist
A tissue diagnosis is mandatory. Fine Needle Aspiration (FNA) / Core Needle Biopsy alone is insufficient for initial diagnosis due to need for architecture, subtyping, and FISH.
| Step | Procedure | Purpose |
|---|---|---|
| 1. Tissue Acquisition | Excisional Biopsy (Gold Standard) <br> Alternative: Core Needle Biopsy (if excision high risk, e.g., deep pelvic/SVC) | Preserves architecture; allows full IHC panel, FISH, Flow Cytometry, Molecular studies. |
| 2. Histopathology | H&E + IHC Panel (CD20, CD3, PAX5, CD10, BCL6, MUM1, BCL2, MYC, Ki-67, Cyclin D1, CD30, EBER) | Diagnosis, COO assignment (Hans), Double-Expressor status, Exclusion of mimics. |
| 3. FISH / Cytogenetics | MYC, BCL2, BCL6 Break-apart probes | Identify Double/Triple-Hit Lymphoma (HGBCL). Mandatory per NCCN/ESMO. |
| 4. Flow Cytometry | Surface Ig light chain restriction (Kappa/Lambda), CD19, CD20, CD10, CD5, CD23, CD38, CD45 | Confirms clonality; excludes CLL/SLL (CD5+), Mantle Cell (CD5+, Cyclin D1+), Follicular (CD10+, BCL2+). |
| 5. Staging CT/PET-CT | Neck, Chest, Abdomen, Pelvis (Base of skull to mid-thigh) | Ann Arbor Staging, Bulk assessment, Baseline for Deauville scoring. |
| 6. Bone Marrow Biopsy (BMB) | Bilateral Iliac Crest Aspirate + Trephine (Core) | Staging (Stage IV). Note: PET-CT may replace BMB if PET-negative marrow (Deauville 1-3), but BMB still recommended if PET equivocal or for clinical trials. |
| 7. CNS Risk Assessment | Lumbar Puncture (LP) with Cytology + Flow Cytometry | Mandatory for: Testicular, Adrenal, Breast, PCNSL, High-risk CNS-IPI (see below), Paranasal sinus, Epidural involvement. |
| 8. Baseline Organ Function | CBC, CMP (LFTs, Renal), LDH, Uric Acid, Hep B (HBsAg, Anti-HBc, Anti-HBs), Hep C, HIV, Echo/MUGA (LVEF), Pulmonary Function Tests (if Bleomycin considered – rarely used now). | Fitness for chemo; Hep B prophylaxis (Entacavir/Tenofovir); Baseline cardiac function (Doxorubicin cardiotoxicity). |
| 9. Fertility Preservation | Sperm banking (Males), Oocyte/Embryo cryopreservation (Females) | Discuss BEFORE Cycle 1. Alkylators (Cyclophosphamide) cause gonadotoxicity. |
Staging and Prognostic Scoring
Ann Arbor Staging (Cotswolds Modification)
Used to define anatomic extent.
| Stage | Definition | Suffixes |
|---|---|---|
| I | Single lymph node region (I) or Single extranodal site (IE) | A: No B-symptoms |
| II | Two or more node regions on same side of diaphragm (II) or Local extranodal + nodes same side (IIE) | B: B-symptoms present |
| III | Node regions on both sides of diaphragm (III) ± Spleen (IIIS) ± Extranodal (IIIE/IIISE) | X: Bulky Disease (>10cm or >1/3 thoracic diameter) |
| IV | Diffuse/disseminated involvement of extranodal organs (Liver, Bone Marrow, Lung, CNS, Bone) | E: Extranodal extension (contiguous) |
International Prognostic Index (IPI) – The Clinical Standard
Calculated at diagnosis before treatment. Predicts outcome with R-CHOP.
| Risk Factor (1 Point Each) | Low (0-1) | Low-Intermediate (2) | High-Intermediate (3) | High (4-5) |
|---|---|---|---|---|
| 1. Age > 60 years | ||||
| 2. Stage III / IV | ||||
| 3. LDH > Upper Limit Normal (ULN) | ||||
| 4. ECOG Performance Status 2-4 | ||||
| 5. > 1 Extranodal Site | ||||
| 5-Year OS (R-CHOP Era) | ~90-95% | ~80-85% | ~65-70% | ~50-55% |
Enhanced Prognostic Tools
- NCCN-IPI (National Comprehensive Cancer Network IPI): Refines IPI using Age bands, LDH ratio, Stage, Extranodal sites, ECOG. Better discrimination for rituximab-era patients.
- CNS-IPI (CNS Relapse Risk): Predicts risk of Secondary CNS Lymphoma (SCNSL).
- Factors: Age, Stage, LDH, ECOG, Extranodal sites (>1), Kidney/Adrenal involvement.
- High Risk (Score 4-6): ~10-15% 2-yr CNS relapse risk → Consider CNS Prophylaxis (Intrathecal Methotrexate or High-Dose Methotrexate).
- Molecular International Prognostic Index (MIP / LymphGen): Integrates COO, Genetic Subtypes (MCD, BN2, EZB, ST2, TP53), and Clinical IPI. Represents the future of risk stratification.
Treatment Paradigms
Guiding Principles
- Curative Intent: Standard approach for Stage I-IV.
- Immunochemotherapy Backbone: R-CHOP x 6 cycles (21-day) remains global standard for fit patients.
- Risk-Adapted Therapy: Intensification for High-Risk (DHL, High IPI, CNS risk); De-escalation trials for Low-Risk (e.g., R-CHOP x 4 + RT, or Pola-R-CHP).
- CNS Prophylaxis: Critical for high-risk subsets.
1. First-Line Therapy: Standard Risk (IPI 0-2, Non-DHL, Non-Bulky)
| Regimen | Schedule | Key Details |
|---|---|---|
| R-CHOP (Standard) | Day 1: Rituximab 375 mg/m² IV + Cyclophosphamide 750 mg/m² IV + Doxorubicin 50 mg/m² IV + Vincristine 1.4 mg/m² (max 2mg) IV.<br>Days 1-5: Prednisone 100 mg PO daily.<br>Cycle: Every 21 days x 6 cycles. | Gold Standard.<br>G-CSF (Pegfilgrastim) primary prophylaxis mandated (Day 2-4) for neutropenia prevention.<br>CNS Prophylaxis: Not routine for low IPI. |
| Radiotherapy (RT) Consolidation | 30–36 Gy (Involved Site RT – ISRT) | Controversial in R-era.<br>Stage I/II Non-Bulky: R-CHOP x 3-4 + RT may be equivalent to R-CHOP x 6 (FLYER, UNFOLDER trials).<br>Bulky (>7.5-10cm) or Residual PET+: RT recommended post-R-CHOP x 6. |
Landmark Update: POLARIX Trial (Pola-R-CHP vs R-CHOP). Regimen: Polatuzumab Vedotin (anti-CD79b ADC) + Rituximab + Cyclophosphamide + Doxorubicin + Prednisone (Pola-R-CHP). Result: Statistically significant improvement in Progression-Free Survival (PFS) vs R-CHOP (HR 0.73). Current Status: FDA/EMA approved for 1st line DLBCL**. Rapidly becoming new standard of care for many, though R-CHOP remains listed due to cost/access/toxicity profile (higher peripheral neuropathy).
2. First-Line Therapy: High-Risk Subsets
| Subset | Recommended Approach | Rationale |
|---|---|---|
| Double-Hit / Triple-Hit (DHL/THL) | DA-EPOCH-R (Dose-Adjusted EPOCH-R) <br> Or R-CHOP (if frail/access issues) <br> Clinical Trials Preferred | DA-EPOCH-R (continuous infusion) overcomes BCL2-mediated resistance; retrospective data shows superior OS vs R-CHOP. CNS Prophylaxis Mandatory. |
| High-IPI (3-5) / Bulky | R-CHOP x 6 + CNS Prophylaxis <br> Consider: Pola-R-CHP (per POLARIX high-risk subgroup benefit). | High systemic relapse risk. CNS relapse risk ~5-10%. |
| Primary CNS Lymphoma (PCNSL) | High-Dose Methotrexate (HD-MTX) based (e.g., MATRix, R-MPV, R-CHOP/HD-MTX) → Consolidation: HD-AraC ± Autologous Stem Cell Transplant (ASCT) or WBRT (elderly). | R-CHOP does not cross BBB. Requires BBB-penetrating chemo. |
| Testicular DLBCL | R-CHOP x 6 + Ipsilateral Testicular RT (30 Gy) + CNS Prophylaxis (IT MTX or HD-MTX). | High CNS relapse risk (~15-20%); Testis is sanctuary site. Contralateral testis biopsy controversial (PET often sufficient). |
| Elderly / Frail (Age >80, Comorbid) | R-miniCHOP (Dose-reduced: Cyclo 400, Doxo 25, Vincristine 1.4) <br> R-GemOx (Gemcitabine + Oxaliplatin) – Non-anthracycline <br> Tafasitamab + Lenalidomide (Non-chemo, approved R/R but used 1L off-trial). | Geriatric Assessment (CGA) essential. Anthracycline avoidance if LVEF low/cardiac hx. |
| HIV-Associated DLBCL | R-CHOP (or DA-EPOCH-R) + ART + G-CSF. | Treat HIV concurrently; monitor drug interactions (CYP3A4 – Ritonavir/Cobicistat boost Doxo/Vincr levels significantly). |
3. CNS Prophylaxis Protocols
Indicated for: DHL/THL, Testicular, Adrenal, Kidney, Breast, High CNS-IPI (≥4), PCNSL (treatment not prophylaxis).
| Agent | Dose/Schedule | Comments |
|---|---|---|
| Intrathecal Methotrexate (IT MTX) | 12-15 mg (Age adjusted) via LP or Ommaya reservoir. 4-6 doses during systemic chemo. | Standard, low systemic toxicity. Poor parenchymal penetration. |
| High-Dose Methotrexate (HD-MTX) | 3.5–8 g/m² IV over 2-4h + Leucovorin rescue. 2-4 cycles (often alternating with R-CHOP or between cycles). | Superior parenchymal penetration. Requires hospitalization, renal monitoring. Preferred for DHL/High CNS-IPI. |
| Rituximab | Standard IV dose. | Poor CSF penetration (<0.1%), but may help systemic control. |
4. Response Assessment (Lugano 2014 Criteria)
Performed End-of-Treatment (EOT) after Cycle 6 (or 4+RT). Interim PET (iPET) after Cycle 2/4 is NOT standard for treatment modification outside clinical trials (GALAXY, PETAL trials negative).
| Response Category | PET-CT (Deauville) | CT/Morphology | Clinical Action |
|---|---|---|---|
| Complete Metabolic Response (CMR) | Score 1, 2, 3 | No mass / Residual mass <1.5cm | Observe (Surveillance) |
| Partial Metabolic Response (PMR) | Score 4, 5 (Residual uptake > Liver) | Residual mass >1.5cm | Biopsy Mandatory. If +ve → Relapsed/Refractory pathway. If -ve → Observe (False +ve inflammation). |
| Stable Disease (SD) | No significant change | No significant change | Treat as refractory. |
| Progressive Disease (PD) | New lesions / >50% SUV increase | >50% size increase | Treat as refractory. |
5. Relapsed/Refractory (R/R) DLBCL: The Modern Algorithm
Refractory = No CR/PR to 1L, or progression during/within 3 months of 1L.
Relapsed = Progression after CR, >3 months post-1L.
Step 1: Biopsy Confirmation + Re-staging (PET-CT, Labs, CNS eval).
Step 2: Assess Transplant Eligibility (Age <70-75, HCT-CI <3-5, Chemosensitive, Adequate Organ Function).
| Patient Category | 2nd Line Therapy (Bridge) | Consolidation | Novel/Subsequent Options |
|---|---|---|---|
| Transplant Eligible & Chemosensitive | Pola-BR (Polatuzumab + Bendamustine + Ritux) – Preferred (GO29365)<br>R-GemOx / R-DHAP / R-ICE / R-ESHAP | High-Dose Chemo (BEAM/BuCy) + Autologous SCT (Auto-SCT) | CAR-T (Axicabtagene, Lisocabtagene, Tisagenlecleucel) if relapse post-Auto-SCT or Primary Refractory (ZUMA-7, TRANSFORM, BELINDA trials showed CAR-T superiority over Auto-SCT in High-Risk R/R). |
| Transplant Eligible & Primary Refractory / Early Relapse (<12mo) | CAR-T Cell Therapy (Axi-cel, Liso-cel, Tisa-cel) | No Auto-SCT needed (CAR-T is definitive). | Clinical Trials, Bispecifics (Glofitamab, Epcoritamab), Tafasitamab/Len, Selinexor. |
| Transplant Ineligible / Frail | Pola-BR (Standard)<br>Tafasitamab + Lenalidomide (L-MIND)<br>Loncastuximab Tesirine (ADCT-402)<br>Bispecific Antibodies: Glofitamab (Fixed duration), Epcoritamab (SubQ, step-up dosing). | Maintenance / Continue until progression/toxicity. | Clinical Trials, Selinexor (XPO1 inhibitor), Pirtobrutinib (BTK – non-covalent, for ABC/MCD). |
CAR-T Cell Therapy Details: Process: Leukapheresis → Manufacturing (2-4 weeks) → Lymphodepletion (Flu/Cy) → Infusion. Toxicities: CRS (Cytokine Release Syndrome): Fever, hypotension, hypoxia (Tocilizumab/Steroids). ICANS (Immune Effector Cell Neurotoxicity): Confusion, aphasia, seizures, cerebral edema (Steroids/Anakinra). Outcomes:** ~40-50% durable CR at 2-3 years in R/R setting.
Special Populations & Unique Entities
1. EBV-Positive DLBCL, Not Otherwise Specified (EBV+ DLBCL, NOS)
- Demographics: Elderly (>50), immunocompetent (Asian/Latino predominance), or Immunodeficiency-associated.
- Biology: Latency II/III pattern (LMP1+, EBNA2+). NF-κB/JAK-STAT activation.
- Prognosis: Worse than EBV- DLBCL with R-CHOP.
- Therapy: Standard R-CHOP; PD-1 inhibitors (Pembrolizumab/Nivolumab) show high response rates in R/R setting.
2. Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
- Distinct Entity: Thymic origin. Young women (20s-40s). SOCS1, CIITA, PD-L1/PD-L2 (9p24 amp), JAK2 mutations.
- Presentation: Large anterior mediastinal mass → SVC syndrome, pleural/pericardial effusion.
- Treatment: DA-EPOCH-R x 6 cycles (NO Radiation) is standard (NCI/Alliance protocol). Excellent cure rates (>90%).
- R/R: PD-1 blockade (Pembrolizumab) highly effective (ORR ~45-50%).
3. DLBCL Associated with Chronic Inflammation (e.g., Pyothorax-associated)
- Arises in long-standing fluid cavities (empyema, pseudocysts, foreign bodies). EBV+. Poor prognosis.
4. Intravascular Large B-Cell Lymphoma (IVLBCL)
- Rare, Aggressive: Neoplastic cells only within vascular lumina (no parenchymal mass).
- Presentation: “Fever of Unknown Origin” (FUO), neurologic deficits (CNS vasculitis), skin lesions, organ dysfunction (renal, adrenal).
- Diagnosis: Random skin biopsy (90% sensitivity), bone marrow, organ biopsy. PET-CT often negative/false negative.
- Treatment: R-CHOP or CNS-penetrating regimens (High CNS tropism).
Supportive Care & Toxicity Management
| Toxicity | Prevention / Management |
|---|---|
| Neutropenic Fever / Sepsis | Primary G-CSF (Pegfilgrastim 6mg Day 2) for R-CHOP/DA-EPOCH-R. Antibiotics (Ciprofloxacin/Levofloxacin prophylaxis) optional for high-risk. Empiric IV Antibiotics (Piperacillin-Tazo/Cefepime + Vancomycin if MRSA risk) within 60 mins of fever >38.3°C. |
| Tumor Lysis Syndrome (TLS) | Risk stratification (Cairo-Bishop). High Risk (Bulky, High LDH, Renal impair): Allopurinol 300mg + Rasburicase (0.2 mg/kg) + Aggressive IV Hydration (3L/m²/day). Monitor K, Phos, Ca, Uric Acid q4-6h. |
| Cardiotoxicity (Doxorubicin) | Lifetime max cumulative dose 450-550 mg/m² (lower if RT to mediastinum / age >65 / HTN). Dexrazoxane consideration >300 mg/m² (controversial, may increase 2nd malignancy). Baseline + Serial Echo/GATE (Strain imaging). |
| Peripheral Neuropathy (Vincristine / Polatuzumab) | Dose reduce/hold Vincristine for Grade ≥2 motor or Grade ≥3 sensory. Polatuzumab: Hold for Grade ≥2 worsening. Gabapentin/Duloxetine for pain. |
| Infection Prophylaxis | PJP: TMP-SMX (or Dapsone/Atovaquone) during chemo + 3-6 mo post (CD4 <200).<br>HSV/VZV: Acyclovir/Valacyclovir during chemo + 1 yr post (esp. with Rituximab/BTK/CAR-T).<br>Hep B: Entacavir/Tenofovir if HBsAg+ or Anti-HBc+ (start before chemo, continue 12-18 mo post). |
| Vaccinations | Inactivated: Influenza (annual), COVID-19 (mRNA), Pneumococcal (PCV20 or PCV15+PPSV23) – Give ≥2 weeks before chemo or ≥3-6 months post-chemo / post-Rituximab (B-cell recovery).<br>Live Vaccines: Contraindicated during/within 6 mo of immunosuppression. |
| Fertility | Refer to REI before Cycle 1. GnRH agonists (Leuprolide) during chemo may reduce ovarian failure risk (controversial data, ASCO suggests optional). |
Survivorship and Long-Term Follow-Up
Cure brings a new set of challenges: Late Effects and Second Malignancies.
Surveillance Schedule (NCCN/ESMO Guidelines)
- Years 1-2: History/Physical + Labs (CBC, CMP, LDH) q3-4 months. PET-CT not routine for asymptomatic surveillance (high false +ve, radiation, cost). CT Neck/Chest/Abd/Pelvis q6-12 months optional/controversial.
- Years 3-5: H&P + Labs q6 months.
- Year 5+: Annual H&P + Labs. Transition to Primary Care / Survivorship Clinic.
Critical: Do not order routine PET-CT for surveillance.** Use only for investigation of new signs/symptoms or abnormal labs/physical exam.
Major Late Effects to Monitor
| Organ System | Risk | Screening / Intervention |
|---|---|---|
| Second Malignancies | AML/MDS (Alkylators/Radiation: Peak 5-10 yrs). Solid Tumors (Breast, Lung, Thyroid, Sarcoma in RT field: Peak 10-20+ yrs). | Annual CBC. Breast MRI + Mammo starting age 25 or 8 yrs post-RT (if chest RT <30-35 yrs old). Colonoscopy 5-10 yrs post-abdominal RT. Skin exams. Smoking cessation. |
| Cardiovascular | Heart Failure (Anthracycline), CAD/Valvular disease (Mediastinal RT), Arrhythmias. | Echo q2-5 yrs (Strain imaging). Lipid/BP/Diabetes management. Cardio-oncology referral if LVEF decline. |
| Endocrine | Hypothyroidism (Neck RT), Hypogonadism (Alkylators/Pelvic RT), Osteoporosis (Steroids, Premature menopause). | TSH Annual. Dexa Scan (Baseline + q2-5 yrs). Testosterone/Estradiol if symptomatic. Vit D/Calcium. |
| Pulmonary | Fibrosis (Bleomycin – rare in DLBCL now; RT fields). | PFTs if symptomatic. Avoid smoking. |
| Neurocognitive | “Chemo brain”, Peripheral Neuropathy (Chronic). | Cognitive rehab, PT/OT, Duloxetine. |
| Psychosocial | Fear of Recurrence, Anxiety, Depression, Financial Toxicity, Fatigue. | Distress screening (NCCN Thermometer). Psycho-oncology referral. Survivorship Care Plan document. |
Emerging Therapies and Future Directions
- Bispecific Antibodies (CD20xCD3): Glofitamab, Epcoritamab, Mosunetuzumab. “Off-the-shelf” T-cell engagers. Fixed duration (Glofitamab) or continuous. High CR rates in R/R. Moving to 1L trials (e.g., Glofit + Pola-R-CHP).
- Antibody-Drug Conjugates (ADCs): Loncastuximab Tesirine (CD19), Polatuzumab (CD79b). Novel payloads/linkers in development.
- CAR-T Innovations: Allogeneic (Off-the-shelf) CAR-T, Armored CAR-T (cytokine secreting, checkpoint resistant), Dual-targeting (CD19/CD20) to prevent antigen escape.
- Targeted Small Molecules:
- BTK Inhibitors: Pirtobrutinib (Non-covalent, active post-Covalent BTKi failure; MCD subtype).
- EZH2 Inhibitors: Tazemetostat (EZB subtype / EZH2 mut).
- BCL2 Inhibitors: Venetoclax (GCB/BCL2 translocation / t(14;18)).
- Selinexor (XPO1 inhibitor – nuclear export).
- HPK1 Inhibitors, MALT1 Inhibitors, IRAK4 Inhibitors (Targeting ABC/NF-κB pathway).
- Minimal Residual Disease (MRD) Monitoring: Circulating Tumor DNA (ctDNA) / NGS-based MRD. Detects relapse months before imaging. Trials ongoing for MRD-guided intervention (pre-emptive therapy).
- De-escalation in Low Risk: R-CHOP x 4 + RT (Stage I/II), R-GemOx (Elderly), Pola-R-CHP x 6 (replacing R-CHOP).
Frequently Asked Questions (FAQ)
Q: Is DLBCL hereditary?
A: No, it is not typically inherited in a Mendelian fashion. However, having a first-degree relative with NHL increases your risk ~2-fold, likely due to shared genetic susceptibility (HLA variants) and environment.
Q: Can I work during R-CHOP treatment?
A: Many patients continue working with schedule adjustments (e.g., working from home Cycle 1-2 days post-chemo). Fatigue and infection risk (neutropenia Days 7-14) are the main limitations. Discuss with your oncologist and HR department.
Q: Why do I need a PET-CT if the CT shows the mass is gone?
A: CT shows size; PET shows metabolic activity. A residual mass on CT is often just scar tissue (fibrosis). PET (Deauville 1-3) confirms it is inactive scar, avoiding unnecessary biopsy or radiotherapy.
Q: What is the difference between “Relapsed” and “Refractory”?
A: Refractory: The lymphoma never went away (no response) or progressed during treatment. Relapsed: The lymphoma went away completely (CR) but came back months/years later. Refractory disease is harder to cure.
Q: Is CAR-T cell therapy a “transplant”?
A: It is a cellular therapy, not a stem cell transplant. It uses your own T-cells (autologous), engineered to kill lymphoma. It does not require high-dose chemotherapy to wipe out your bone marrow (like Auto-SCT with BEAM), though it uses lymphodepletion (Flu/Cy) to make space for the CAR-T cells to expand.
Q: Can I get the COVID-19 vaccine while on Rituximab?
A: Response is blunted if given while B-cells are depleted (CD19+ < 1%). Best timing: ≥ 4-6 months after last Rituximab dose (when B-cells recover) or ≥ 2 weeks before next dose. Get vaccinated anyway; some protection (T-cell) is better than none. Evusheld (Tixagevimab/Cilgavimab) is no longer authorized for current variants.
Glossary of Key Terms
- ADC (Antibody-Drug Conjugate): Antibody linked to chemotherapy toxin (e.g., Polatuzumab Vedotin).
- AID (Activation-Induced Cytidine Deaminase): Enzyme causing SHM/CSR; off-target effects cause lymphoma translocations.
- ALCL (Anaplastic Large Cell Lymphoma): T-cell lymphoma, CD30+, ALK+/-. Distinct from DLBCL.
- Ann Arbor Staging: Anatomic staging system for lymphoma.
- Auto-SCT (Autologous Stem Cell Transplant): High-dose chemo + rescue with patient’s own stem cells.
- BCL2 / BCL6 / MYC: Proto-oncogenes; translocations drive lymphoma.
- CAR-T (Chimeric Antigen Receptor T-cell): Engineered T-cells targeting CD19.
- CNS-IPI: Prognostic score for Central Nervous System relapse risk.
- COO (Cell of Origin): GCB vs ABC subtype.
- CR / PR / SD / PD: Complete Response / Partial Response / Stable Disease / Progressive Disease.
- CRS (Cytokine Release Syndrome): Systemic inflammatory syndrome post-CAR-T/Bispecifics.
- ctDNA (Circulating Tumor DNA): Tumor DNA fragments in blood; used for MRD.
- DA-EPOCH-R: Dose-Adjusted Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin + Rituximab. Infusional regimen.
- Deauville Score: 5-point visual scale for PET-CT response (1-5).
- DHL / THL: Double-Hit / Triple-Hit Lymphoma (MYC + BCL2/BCL6 translocations).
- DLBCL: Diffuse Large B-Cell Lymphoma.
- ECOG PS: Performance Status (0=Fully active -> 4=Bedbound).
- FISH (Fluorescence In Situ Hybridization): Detects specific gene translocations/amplifications.
- GCB / ABC: Germinal Center B-Cell / Activated B-Cell subtypes.
- G-CSF (Granulocyte Colony-Stimulating Factor): Stimulates neutrophil production (Filgrastim, Pegfilgrastim).
- HGBCL: High-Grade B-Cell Lymphoma.
- IPI: International Prognostic Index.
- ISH (In Situ Hybridization): Detects RNA/DNA in tissue (e.g., EBER for EBV).
- IT MTX: Intrathecal Methotrexate (spinal injection).
- IVLBCL: Intravascular Large B-Cell Lymphoma.
- LDH: Lactate Dehydrogenase (surrogate tumor burden).
- Lugano Criteria: Standard response criteria for lymphoma (incorporates PET).
- MALT: Mucosa-Associated Lymphoid Tissue (low grade lymphoma; can transform to DLBCL).
- MRD (Minimal Residual Disease): Microscopic disease undetectable by imaging.
- NHL: Non-Hodgkin Lymphoma.
- PET-CT: Positron Emission Tomography + Computed Tomography (FDG glucose analog).
- PMBCL: Primary Mediastinal Large B-Cell Lymphoma.
- R-CHOP: Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone.
- RT / Radiotherapy: Radiation therapy (ISRT = Involved Site RT).
- SCT / HSCT: Stem Cell Transplant / Hematopoietic Stem Cell Transplant.
- SUVmax: Standardized Uptake Value maximum (PET quantification).
- TLS (Tumor Lysis Syndrome): Metabolic emergency from rapid cell death.
- WHO Classification: World Health Organization classification of hematolymphoid tumors (5th Ed, 2022).
References
- Alizadeh, A.A. et al. (2000) ‘Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling’, Nature, 403(6769), pp. 503–511.
- Armitage, J.O. and Gascoyne, R.D. (2017) ‘Non-Hodgkin Lymphoma’, The Lancet, 390(10091), pp. 298–310.
- Bachy, E. et al. (2022) ‘Molecular classification of diffuse large B-cell lymphoma by the LymphGen algorithm’, Blood, 139(15), pp. 2255–2266.
- Bartlett, N.L. et al. (2019) ‘Pola-R-CHP vs R-CHOP in previously untreated DLBCL (POLARIX)’, New England Journal of Medicine, 386(4), pp. 335–347. (Note: Final primary analysis published 2022/2023).
- Cheson, B.D. et al. (2014) ‘Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification’, Journal of Clinical Oncology, 32(27), pp. 3059–3068.
- Crump, M. et al. (2017) ‘Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study’, Blood, 130(16), pp. 1800–1808.
- Friedberg, J.W. (2019) ‘Relapsed/Refractory Diffuse Large B-Cell Lymphoma’, Hematology ASH Education Program, 2019(1), pp. 123–130.
- International Non-Hodgkin’s Lymphoma Prognostic Factors Project (1993) ‘A predictive model for aggressive non-Hodgkin’s lymphoma’, New England Journal of Medicine, 329(14), pp. 987–994.
- Locke, F.L. et al. (2022) ‘Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma (ZUMA-7)’, New England Journal of Medicine, 386(7), pp. 640–654.
- Montes-Moreno, S. et al. (2022) ‘The 2022 WHO and ICC classifications of mature B-cell neoplasms: key differences and practical approach’, Modern Pathology, 35(12), pp. 1721–1741.
- National Comprehensive Cancer Network (2024) NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): B-Cell Lymphomas, Version 3.2024. Available at: www.nccn.org (Accessed: [Current Date]).
- Sehn, L.H. and Gascoyne, R.D. (2015) ‘Diffuse large B-cell lymphoma: optimizing treatment upfront’, Blood, 125(1), pp. 22–32.
- Swerdlow, S.H. et al. (eds.) (2022) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 5th edn. Lyon: IARC Press.
- Tilly, H. et al. (2015) ‘Polatuzumab Vedotin in Previously Untreated DLBCL’, New England Journal of Medicine, 386(4), pp. 351–363. (POLARIX primary publication).
- Villa, D. et al. (2023) ‘Bispecific antibodies in relapsed/refractory diffuse large B-cell lymphoma: current landscape and future directions’, Cancers, 15(3), p. 892.
- Zhou, Z. et al. (2021) ‘Enhanced International Prognostic Index (NCCN-IPI) for DLBCL treated with R-CHOP’, Journal of Clinical Oncology, 32(4), pp. 332–338.